APG101 constitutes an innovative approach to treating GBM since it has the therapeutic aim to inhibit the invasive growth of glioblastoma cells.
APG101 constitutes an innovative approach to treating GBM. As demonstrated by Kleber et al., the binding of the CD95 ligand to its cognate receptor stimulates the invasive growth of glioblastoma cells.